Skip to main content
. 2019 Jun 4;1(1):vdz005. doi: 10.1093/noajnl/vdz005

Fig. 1.

Fig. 1

Niraparib treatment improved survival and reduced tumor burden in intracranial MDA-MB-436 model of triple-negative breast cancer (TNBC) brain metastases. Survival of mice stereotactically injected with (A) BRCA1-wild-type MDA-MB-231Br, (B) BRCA1-mutant SUM149, or (C) BRCA1-mutant MDA-MB-436 TNBC into the right caudate putamen and treated with vehicle or 50 mg/kg niraparib daily. Intracranial bioluminescent signal of mice stereotactically injected with (D) MDA-MB-231Br, (E) SUM149, or (F) MDA-MB-436 TNBC into the right caudate putamen and treated with vehicle or 50 mg/kg niraparib daily. Weight changes of mice with intracranial (G) MDA-MB-231Br, (H) SUM149, or (I) MDA-MB-436 TNBC treated with vehicle or 50 mg/kg niraparib daily. x-axes indicate the time in days since intracranial implantation of cells up to day 70 (end of study); y-axes indicate the percent of animals surviving (A–C), luciferin bioluminescent signal in photons/s (D–F) or the percent change in body weight relative to day 1 of the study (G–I). n = 9–10 per treatment group.